Open main menu

HemOnc.org - A Hematology Oncology Wiki β

Changes

m
no edit summary
|-
|[https://doi.org/10.1200/JCO.1996.14.3.911 Veerman et al. 1996 (DCOG ALL-VI)]
|{{#subobject:xx|ToDo=1}}1984-1988
| style="background-color:#91cf61" |Non-randomized
| style="background-color:#d3d3d3" |
|-
|[http://www.bloodjournal.org/content/101/10/3809.long Bostrom et al. 2003 (CCG-1922)]
|{{#subobject:xx|ToDo=1}}1993-1995
|style="background-color:#1a9851"|Phase III (E-switch-ic)
|[[#L-Asparaginase.2C_Vincristine.2C_Prednisone|L-asparaginase, Vincristine, Prednisone]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2005.05509.x/full Mitchell et al. 2005 (UK MRC ALL97)]
|{{#subobject:xx|ToDo=1}}1997-2002
|style="background-color:#1a9851"|Phase III (E-switch-ic)
|[[#L-Asparaginase.2C_Vincristine.2C_Prednisolone|L-asparaginase, Vincristine, Prednisolone]]
===Regimen {{#subobject:4af0d5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!style="width: 2520%"|Study!style="width: 2520%"|Years of enrollment!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]!style="width: 2520%"|Comparator!style="width: 2520%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
|-
|[https://www.nature.com/articles/2401704 Hann et al. 2000 (MRC UKALL XI)]
|1990-1997
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2005.05509.x/full Mitchell et al. 2005 (UK MRC ALL97)]
|1997-2002
|style="background-color:#1a9851"|Phase III (C)
|[[#L-Asparaginase.2C_Vincristine.2C_Dexamethasone|L-asparaginase, Vincristine, Dexamethasone]]
|-
|[http://www.bloodjournal.org/content/64/1/267.long Gottlieb et al. 1984 (CALGB 7612)]
|{{#subobject:xx|ToDo=1}}1976-1980
|style="background-color:#1a9851"|Randomized (C)
|[[B-cell_acute_lymphoblastic_leukemia#DOLP|DOLP]]
|-
|[https://pubmed.ncbi.nlm.nih.gov/2665546 van der Does-van den Berg et al. 1989 (DCLSG ALL V)]
|{{#subobject:xx|ToDo=1}}1979-1982
|style="background-color:#1a9851"|Phase III (C)
|[[B-cell_acute_lymphoblastic_leukemia#DOLP|DOLP]]
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2141.1991.tb04415.x Eden et al. 1991 (MRC UKALL VIII)]
|{{#subobject:xx|ToDo=1}}1979-1982
|style="background-color:#1a9851"|Phase III (C)
|[[B-cell_acute_lymphoblastic_leukemia#DOLP|DOLP]]
|-
|[https://doi.org/10.1200/JCO.1993.11.3.527 Tubergen et al. 1993 (CCG-105)]
|{{#subobject:xx|ToDo=1}}1983-1989
|style="background-color:#1a9851"|Phase III (C)
|[[B-cell_acute_lymphoblastic_leukemia#DOLP|DOLP]]
|-
|[http://www.bloodjournal.org/content/101/10/3809.long Bostrom et al. 2003 (CCG-1922)]
|{{#subobject:xx|ToDo=1}}1993-1995
|style="background-color:#1a9851"|Phase III (C)
|[[#L-Asparaginase.2C_Vincristine.2C_Dexamethasone|L-asparaginase, Vincristine, Dexamethasone]]
LookupUsers, editors, emailconfirmed
24,770
edits